



Perma-Fix Medical Provides Business Update

Schedules Investor Webcast for April 14th at 2:00 PM Central European Time

Wroclaw – April 14, 2016 – Perma-Fix Medical S.A. (WAR: PFM) today provided a general business update for the fourth quarter and full year ended December 31, 2015. The Company also announced it will host a business update call at 2:00 PM Central European time (8:00 a.m. Eastern time) on Thursday, April 14, 2016, via webcast on the company's website: www.medical-isotope.com.

Stephen Belcher, Chief Executive Officer of Perma-Fix Medical S.A. stated, "We are pleased to report a number of important developments this past year which have helped advance the commercialization of our innovative process to produce Technetium-99m (Tc-99m), the most widely used medical isotope in nuclear medical imaging procedures all over the world."

"First, in early 2015 the U.S. Patent & Trademark Office issued Perma-Fix Environmental Services Inc. a composition of matter patent for our microporous composite material and its applications, which provides us very broad intellectual property protection."

"Second, we completed three successful scale-ups of our prototype generator for commercial production of Tc-99m. The tests confirmed that our proprietary resin could withstand higher levels of radiation, up to 6 curies. Based on these results, we remain convinced that our process has the potential to reshape the multi-billion dollar global supply chain of Tech-99 in the United States and around the world. We not only exceeded industry requirements in many emerging markets, but we have also demonstrated our superiority over traditional processes in the North American and European markets. We believe we have mitigated the technology, regulatory, and commercial risks related to our technology."

"Third, we finalized our agreement with Digirad Corporation (NASDAQ: DRAD), the leading user of Tc-99m in the U.S. Digirad invested \$1 million into the company at a significant premium to the current market price, which is further illustration of the growing interest in our process from within the industry. As part of the long-term supply agreement, Digirad will purchase agreed upon quantities of Tc-99m for its nuclear imaging operations upon receiving regulatory clearance for our process."

"Fourth, given our rapid progress, we made some important additions to the senior management team and Supervisory Board, who bring relevant experience that will be valuable as we continue to expand our industry relationships in advance of submitting our applications for U.S. Food and Drug Administration ("FDA") and European CE marketing approval."

"Next was the formal acceptance of a \$2.8 million grant awarded to a consortium Perma-Fix Medical led for further development, testing and commercialization of a novel prototype generator for the production of Tc-99m for cancer and cardiac imaging. In December, we signed the agreement with the National Centre for Research and Development in Poland concerning preparation and financing of the project. The allocation came from the STRATEGMED Program in Poland."

“As a result of all these developments, we remain extremely encouraged by the outlook for the business, as our process has been validated at two leading nuclear institutions, including POLATOM in Warsaw, Poland and the Missouri University Research Reactor (MURR) in Columbia, Missouri, USA, demonstrating that our system is able to produce Tech-99 in commercial quantities. The feedback from within the industry, both distributors and end-users, has been positive. We believe that our production process provides an unmatched value proposition, while addressing the global need for a safer, more reliable, more cost-effective and uranium-free solution to Tech-99m production. In addition, our process can be easily deployed in standard research and commercial reactors worldwide and it encompasses full production cycle from reactor to final medical supply.”

Mr. Belcher concluded, “We recently announced plans to list on the NASDAQ market in the United States later this year. We will provide further announcements regarding the anticipated timing of a NASDAQ listing based on market conditions in the U.S. Current investors will maintain the same equity ownership percentage in any new corporate structure prior to any potential future capital raise in the U.S. We believe the NASDAQ listing would provide us greater access to North American and global healthcare and life science investors. We strongly believe this model will provide our current and future investors with improved share liquidity and has a potential to maximize shareholder value.”

The conference call can be accessed via a live Internet webcast on the Company's website at www.medical-isotope.com. A webcast replay of the conference call will be accessible on the Company's website at www.medical-isotope.com for 90 days.

About Perma-Fix Medical

Perma-Fix Medical S.A. was formed to develop, obtain FDA and other regulatory approval and commercialize a new process to produce Technetium-99 (Tc-99m), the most widely used medical isotope in the world. The new process is expected to solve worldwide shortages of Tc-99m as it is less expensive, does not require the use of government-subsidized, weapons-grade materials and can be easily deployed around the world using standard research and commercial reactors, thereby eliminating the need for special purpose reactors. Please visit us on the World Wide Web at <http://www.medical-isotope.com>.

Contacts:

Justyna Gudaszevska or David K. Waldman
Crescendo Communications Europe Sp. z o.o
Tel: (+48) 693 354 580
Email : pfm@crescendo-ir.com